GLP-1 RA treatment was associated with improvement of chronic spontaneous urticaria (CSU), suggesting immunomodulatory effects on mast cell-driven skin inflammation beyond metabolic benefits.
Hives improve on GLP-1GLP-1 drugs' immunomodulatory effects extend to chronic hives — suppressing the mast cell activation driving this common skin condition
What the researchers found
GLP-1 RA treatment associated with CSU improvement, suggesting immunomodulatory effects on mast cell-driven inflammation and immune dysregulation beyond metabolic benefits.
Why it matters
CSU affects 1-2% of the population with limited treatment options. GLP-1 drugs could provide a new therapeutic approach.
How the study worked
Documentation of CSU improvement during GLP-1 RA treatment with immunomodulatory mechanism discussion.
What this study cannot tell us
Case-level evidence. Cannot prove causation. Mechanism speculative.
How to read the evidence
Case-level evidence with immunomodulatory rationale.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs' immunomodulatory properties extend to mast cell-driven diseases, potentially helping millions with allergic and autoimmune skin conditions.
Questions still open
- Would a dedicated CSU trial of GLP-1 drugs show efficacy?
- Which GLP-1 drug is most effective for CSU?
- Does the CSU improvement persist after stopping GLP-1 drugs?
Common questions
Can GLP-1 drugs help chronic hives?
Is this a proven treatment for hives?
Read the original research
Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.
Dermatology and therapy, 16(2), 1419-1425
Citation
Kwiek, Bartłomiej; Sieczych, Julia; Łukowska, Katarzyna; Ambroziak, Marcin. (2026). Improvement of Chronic Spontaneous Urticaria After Glucagon-Like Peptide 1 Receptor Agonist Therapy: Report of Two Cases.. Dermatology and therapy, 16(2), 1419-1425. https://doi.org/10.1007/s13555-025-01640-7